Effect of Vitamin E Supplementation on Plasma Lipid,Apolipoprotein and Lipoprotein Profiles in Patients on PeritonealDialysis and Hemodialysis

Dyslipidemia is one of the well known risk factor for cardiovascular disease in patients on dialysis. The aim of the present study was to assess the influence of vitamin E therapy on lipid profile in patients on hemodialysis (HD) and peritoneal dialysis (PD). .
This was a case-control study. The study was performed on 34 HD patients, 13 PD patients and 22 healthy volunteers with a mean age of 45.57 ± 8.54 years. HD patients were divided into two groups, i.e. treatment (n=19) and control (n=15). Vitamin E was administered, 300 mg/day, to the HD treatment group and PD patients for 20 weeks. Plasma total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very-low density lipoprotein cholesterol, apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) were examined before and after vitamin E treatment..
Before vitamin E treatment, the levels of high-density lipoprotein cholesterol were significantly lower in the HD patient group (35.91±10.54 mg/dl) and PD group (37.92±7.19 mg/dl) than the healthy group (44.27±8.33 mg/dl), (p=0.008). Before the treatment the levels of lipoprotein(a) were significantly higher in the HD group (28.12±10.85 mg/dl) and PD group (31.64±15.12 mg/dl) than the healthy group (22.09±9.05 mg/dl), (p=0.008). Lipid and lipoprotein levels in HD and PD groups were not changed significantly after vitamin E treatment. .
Vitamin E supplementation is not effective on lipid and lipoprotein levels in patients on HD and PD. .